JNJ-1887 Development Halted Following Phase 2b Data Review

Johnson & Johnson (JNJ) has decided to discontinue the development program for JNJ-1887, a gene therapy being developed to treat Geographic Atrophy (GA), the late-stage form of Age-related Macular Degeneration (AMD). This decision follows an analysis of the topline data from the Parasol Phase 2b study, which was a key milestone for J&J in 2026. The primary endpoint of the clinical trial, the reduction rate of Geographic Atrophy lesion size, did not show a statistically significant difference compared to the control group, leading to the conclusion that the candidate had limited commercial potential. The discontinuation of this promising next-generation innovative drug candidate in the ophthalmic disease market has created a significant gap in J&J's mid- to long-term ophthalmic R&D pipeline.

Limitations in the Efficacy of the Mechanism of Complement Inhibition via Soluble CD59 Expression

JNJ-1887 (formerly HMR59) was an innovative gene therapy that expresses soluble CD59 protein via an Adeno-Associated Virus serotype 2 (AAV2) vector. This therapy was designed to be administered via a single intravitreal injection, inhibiting the activation of the complement system in the eye and preventing retinal cell damage. J&J acquired this asset by acquiring Hemera Biosciences in 2020 and initiated a large-scale Phase 2b clinical trial in 2023, involving 305 patients over 18 months. However, the approach of directly targeting the Membrane Attack Complex (MAC), a key component of the Complement Terminal Pathway, did not translate into a sufficient reduction in lesion area in patients in the real-world clinical setting, resulting in a failure to demonstrate clinical efficacy.

Intense Competition in the Geographic Atrophy Treatment Market

Currently, the Geographic Atrophy market has a high unmet need, and global pharmaceutical companies are competing fiercely, viewing it as a promising blue ocean market. Apellis' Syfovre (pegcetacoplan) and Iveric Bio's Izervay (avacincaptad pegol) are already approved as standard of care and have captured a significant share of the market. In this context, the discontinuation of JNJ-1887, a gene therapy that aimed for long-term efficacy with a single injection, is a significant setback for J&J. With Sanofi conducting a Phase 2 trial of SAR446597, a gene therapy that simultaneously blocks both the Classical Pathway and the Alternative Pathway, the development of alternative technologies is accelerating, and J&J's market position is likely to weaken further.

Bold Portfolio Restructuring for R&D Efficiency

J&J's decision goes beyond the failure of a single drug and reflects the company's overall strategy of improving R&D efficiency and reallocating R&D resources. Recently, J&J returned the rights to botaretigene sparoparvovec, a gene therapy for rare ophthalmic diseases, to MeiraGTx for $25 million and discontinued the development of two CAR-T cell therapies. This move is in line with the trend of large pharmaceutical companies streamlining their portfolios by focusing R&D resources on late-stage assets with a higher probability of success and greater commercial value. Although J&J is retreating from the field of ophthalmic gene therapy, it remains committed to applying the lessons learned from the Parasol study to its early-stage pipeline to minimize risks.